Who is affected by this change?

This affects Independence Blue Cross Oncology, Pulmonology providers on Commercial plans.

When does this change take effect?

This change is effective Mar 5, 2025.

Back to dashboard

CommercialCoverageLow impact

06.02.49b, VeriStrat® Testing for Targeted Therapy in Non-Small Cell Lung Cancer

Independence Blue Cross·Oncology, Pulmonology·Pharmacy

Effective date

Mar 5, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

VeriStrat® Testing policy for Non-Small Cell Lung Cancer has been reissued with an effective date of March 5, 2025. This is a pharmacy-related policy update that affects targeted therapy testing, but specific coverage details are not available from the summary.

Action Required

Action needed

By March 5, 2025: Billing team should review the full policy document at the provided URL to understand any changes to VeriStrat® Testing coverage and billing requirements for Non-Small Cell Lung Cancer targeted therapy. Update billing procedures accordingly once full policy details are reviewed.

Related policy hubs

Independence Blue Cross policies Oncology Pulmonology